Jia Ruan

6.5k total citations
148 papers, 3.5k citations indexed

About

Jia Ruan is a scholar working on Pathology and Forensic Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Jia Ruan has authored 148 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 99 papers in Pathology and Forensic Medicine, 63 papers in Oncology and 40 papers in Molecular Biology. Recurrent topics in Jia Ruan's work include Lymphoma Diagnosis and Treatment (99 papers), Chronic Lymphocytic Leukemia Research (38 papers) and CAR-T cell therapy research (21 papers). Jia Ruan is often cited by papers focused on Lymphoma Diagnosis and Treatment (99 papers), Chronic Lymphocytic Leukemia Research (38 papers) and CAR-T cell therapy research (21 papers). Jia Ruan collaborates with scholars based in United States, China and United Kingdom. Jia Ruan's co-authors include John P. Leonard, Peter Martin, Richard R. Furman, Morton Coleman, Rebecca Elstrom, Carl Nathan, Amy Chadburn, Paul J. Christos, Yongxin Li and Michael U. Shiloh and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Jia Ruan

137 papers receiving 3.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jia Ruan United States 32 1.8k 1.5k 974 909 513 148 3.5k
Piotr Smolewski Poland 32 651 0.4× 815 0.5× 1.8k 1.9× 660 0.7× 801 1.6× 172 3.5k
Charles M. Farber United States 24 1.1k 0.6× 780 0.5× 369 0.4× 648 0.7× 277 0.5× 89 2.3k
Claude Linassier France 28 721 0.4× 738 0.5× 786 0.8× 262 0.3× 170 0.3× 97 2.7k
Michael O’Dwyer Ireland 40 404 0.2× 983 0.7× 2.0k 2.0× 853 0.9× 973 1.9× 162 4.3k
Sherif Ibrahim Egypt 28 417 0.2× 695 0.5× 1.4k 1.5× 438 0.5× 610 1.2× 107 3.2k
John J. Kavanagh United States 39 384 0.2× 1.4k 1.0× 1.5k 1.5× 132 0.1× 502 1.0× 121 4.7k
Kohichi Takada Japan 28 286 0.2× 854 0.6× 1.7k 1.7× 419 0.5× 330 0.6× 172 3.7k
David Loury United States 18 702 0.4× 357 0.2× 1.0k 1.1× 980 1.1× 551 1.1× 31 2.6k
A. B. Deisseroth United States 29 255 0.1× 1.0k 0.7× 1.2k 1.2× 450 0.5× 658 1.3× 79 3.1k
Masayoshi Namba Japan 35 422 0.2× 1.1k 0.8× 2.8k 2.8× 255 0.3× 430 0.8× 186 4.8k

Countries citing papers authored by Jia Ruan

Since Specialization
Citations

This map shows the geographic impact of Jia Ruan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jia Ruan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jia Ruan more than expected).

Fields of papers citing papers by Jia Ruan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jia Ruan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jia Ruan. The network helps show where Jia Ruan may publish in the future.

Co-authorship network of co-authors of Jia Ruan

This figure shows the co-authorship network connecting the top 25 collaborators of Jia Ruan. A scholar is included among the top collaborators of Jia Ruan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jia Ruan. Jia Ruan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ruan, Jia, et al.. (2024). Update on T-Cell Lymphoma Epidemiology. Current Hematologic Malignancy Reports. 19(3). 93–103. 6 indexed citations
2.
3.
Wang, Jacqueline, Jihao Zhou, Han W. Tun, et al.. (2024). Association of Sex, Race and Ethnicity with Clinical Characteristics and Survival Outcomes of Mantle Cell Lymphoma: A National Cancer Database Study. Blood. 144(Supplement 1). 1637–1637.
4.
Freeman, Daniel J., Catherine Diefenbach, Linda Lam, et al.. (2024). terraFlow, a high-parameter analysis tool, reveals T cell exhaustion and dysfunctional cytokine production in classical Hodgkin’s lymphoma. Cell Reports. 43(8). 114605–114605. 3 indexed citations
5.
Zhu, Tong, Jia Ruan, Xin Su, et al.. (2023). A novel DNAzyme-driven walker-walkers serial amplified electrochemical aptasensor for ultrasensitive detection of cardiac troponin I. Microchemical Journal. 191. 108756–108756. 2 indexed citations
6.
Ruan, Jia, Jasmine M. Zain, Borko Jovanovic, et al.. (2023). Multicenter phase 2 study of romidepsin plus lenalidomide for previously untreated peripheral T-cell lymphoma. Blood Advances. 7(19). 5771–5779. 19 indexed citations
7.
Liberto, Maurizio Di, Yang Hu, Xiangao Huang, et al.. (2023). Harnessing Btki Therapy By CDK4/6i Control of T Effector Memory Cells and T Cell Surveillance in Mantle Cell Lymphoma. Blood. 142(Supplement 1). 50–50.
8.
Cayrol, Florencia, María V. Revuelta, Jude M. Phillip, et al.. (2022). Inhibition of Integrin αVβ3 Signaling Improves the Antineoplastic Effect of Bexarotene in Cutaneous T-Cell Lymphoma. Molecular Cancer Therapeutics. 21(9). 1485–1496. 4 indexed citations
9.
Grossman, Marc E., Jia Ruan, & Cynthia M. Magro. (2022). Epstein-Barr virus-positive, CD30-positive, diffuse large B-cell lymphoma in a patient with angioimmunoblastic T-cell lymphoma. JAAD Case Reports. 25. 58–62.
10.
Pang, Brendan, Yong‐Guan Zhu, Jing Ni, et al.. (2020). Quality Assessment and Comparison of Plasma-Derived Extracellular Vesicles Separated by Three Commercial Kits for Prostate Cancer Diagnosis. SHILAP Revista de lepidopterología. 1 indexed citations
11.
Ruan, Jia, Peter Martin, Paul J. Christos, et al.. (2017). Initial Treatment with Lenalidomide Plus Rituximab for Mantle Cell Lymphoma: 5-Year Follow-up and Correlative Analysis from a Multi-Center Phase II Study. Blood. 130. 154–154. 7 indexed citations
12.
Martin, Peter W., Sin‐Ho Jung, Brandelyn N. Pitcher, et al.. (2017). A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin’s lymphoma (NHL): CALGB 50803 (Alliance). Annals of Oncology. 28(11). 2806–2812. 55 indexed citations
13.
Pera, Benet, Tiffany Tang, Rossella Marullo, et al.. (2016). Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients. Clinical Epigenetics. 8(1). 79–79. 40 indexed citations
14.
Song, Kai, Brett H. Herzog, Minjia Sheng, et al.. (2013). Lenalidomide Inhibits Lymphangiogenesis in Preclinical Models of Mantle Cell Lymphoma. Cancer Research. 73(24). 7254–7264. 50 indexed citations
15.
16.
Thompson, Carrie A., Martin T. Wells, Richard R. Furman, et al.. (2010). Surveillance CT scans are a source of anxiety and fear of recurrence in long-term lymphoma survivors. Annals of Oncology. 21(11). 2262–2266. 133 indexed citations
17.
Elstrom, Rebecca, Peter Martin, Jacqueline C. Barrientos, et al.. (2010). Response to Second-line Therapy Defines the Potential for Cure in Patients With Recurrent Diffuse Large B-Cell Lymphoma: Implications for the Development of Novel Therapeutic Strategies. Clinical Lymphoma Myeloma & Leukemia. 10(3). 192–196. 41 indexed citations
18.
Martin, Peter, Amy Chadburn, Paul J. Christos, et al.. (2009). Outcome of Deferred Initial Therapy in Mantle-Cell Lymphoma. Journal of Clinical Oncology. 27(8). 1209–1213. 234 indexed citations
19.
Coleman, Morton, Peter Martin, Jia Ruan, et al.. (2008). Low-dose metronomic, multidrug therapy with the PEP-C oral combination chemotherapy regimen for mantle cell lymphoma. Leukemia & lymphoma. 49(3). 447–450. 35 indexed citations
20.
Calingasan, Noel Y., Daniel Ho, Elizabeth Wille, et al.. (2008). Influence of mitochondrial enzyme deficiency on adult neurogenesis in mouse models of neurodegenerative diseases. Neuroscience. 153(4). 986–996. 60 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Piotr Smolewski Breakdown of academic impact, for papers by Charles M. Farber Breakdown of academic impact, for papers by Claude Linassier Breakdown of academic impact, for papers by Michael O’Dwyer Breakdown of academic impact, for papers by Sherif Ibrahim Breakdown of academic impact, for papers by John J. Kavanagh Breakdown of academic impact, for papers by Kohichi Takada Breakdown of academic impact, for papers by David Loury Breakdown of academic impact, for papers by A. B. Deisseroth Breakdown of academic impact, for papers by Masayoshi Namba
Rankless by CCL
2026